This technology identifies the nucleoside triphosphate diphosphohydrolases 8 (NTPDase8) as a therapeutic target for liver ischemia-reperfusion injury.
Liver ischemia-reperfusion (I/R) injury causes significant hepatic parenchymal damage due to a temporary disruption of portal or hepatic arterial inflow, followed by restoration. Although liver I/R injury can result from several pathological conditions, including systemic shock, its pathogenesis is complex, and few therapeutics currently target the molecular events that lead to tissue damage.
This technology describes the protective role of nucleoside triphosphate diphosphohydrolases 8 (NTPDase8) in the liver as a critical suppressor of the inflammatory and metabolic responses to liver ischemia-reperfusion (I/R) injury. NTPDase8, expressed on parenchymal liver cells, modulates the extracellular levels of purine nucleotides and nucleosides, thereby reducing hepatic injury after I/R. Exogenous administration or endogenous overexpression of NTPDase8 represents a potential strategy for preventing or treating liver I/R injury.
This technology has been validated in in vivo models of liver I/R injury.
Patent Pending
IR CU25127
Licensing Contact: Kristin Neuman
